Compare Kimberly Clark Corp (KMB) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Tempus AI — how do they compare? Kimberly Clark Corp trades at $97.59 (market cap $32.51B), while Tempus AI trades at $70.93 (market cap $12.58B). The key difference: Kimberly Clark Corp is far larger — about 2.6× Tempus AI's market cap, and Kimberly Clark Corp pays a 5.24% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and Tempus AI for 23 Days on average.
| KMB | TEM | |
|---|---|---|
Market Cap | $32.51B | $12.58B |
Volume | 6,139,913 | 7,444,569 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $121.44 | $99.28 |
52-Week Low | $93.05 | $41.55 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $38.07B | $13.21B |
Dividend Yield | 5.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.74, up 1.31% on the day, with a bearish technical outlook and mixed fundamentals. Recent earnings show a Q2 2026 miss but beats in prior quarters, while revenue declined to $16.45B in 2025. The company maintains a strong dividend yield of over 5% with 54 consecutive years of increases, but cash flow trends raise sustainability questions amid its pending Kenvue acquisition.
KMB offers value with a P/E of 19.32 and analyst consensus target of $117.25, implying 20% upside, but risks include integration challenges from the Kenvue deal, litigation liabilities, and pressured cash flows. The stock's high ROE of 129.43% signals efficient capital use, yet investor sentiment is cautious due to near-term execution hurdles.
Tempus AI (TEM) trades at $69.28, down 1.44% today, with a bullish technical signal despite bearish moving averages. The company shows strong revenue growth (2026: $1.4B) but remains unprofitable with negative margins. Recent FDA clearance for ECG-MR AI product and ESMO Congress presentations highlight innovation momentum. Analyst consensus is strongly bullish with 64% buy ratings and $72.60 price target.
TEM offers growth potential in AI-driven healthcare diagnostics but carries significant execution risk due to persistent losses. The stock's high P/S ratio (8.61) reflects growth expectations, yet negative ROE (-67.44%) and insider selling warrant caution. Upside depends on profitability improvements and commercial adoption of new AI products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
